Cargando…

Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab

Novel predictive biomarkers are needed to improve patient selection and optimize the use of bevacizumab (B) in metastatic colorectal cancer. We analyzed the potential of five circulating biomarkers to predict B efficacy and monitor response. Peripheral blood samples collected at baseline, at the fir...

Descripción completa

Detalles Bibliográficos
Autores principales: Marisi, Giorgia, Scarpi, Emanuela, Passardi, Alessandro, Nanni, Oriana, Ragazzini, Angela, Valgiusti, Martina, Casadei Gardini, Andrea, Neri, Luca Maria, Frassineti, Giovanni Luca, Amadori, Dino, Ulivi, Paola
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431064/
https://www.ncbi.nlm.nih.gov/pubmed/28465540
http://dx.doi.org/10.1038/s41598-017-01420-0
_version_ 1783236360034844672
author Marisi, Giorgia
Scarpi, Emanuela
Passardi, Alessandro
Nanni, Oriana
Ragazzini, Angela
Valgiusti, Martina
Casadei Gardini, Andrea
Neri, Luca Maria
Frassineti, Giovanni Luca
Amadori, Dino
Ulivi, Paola
author_facet Marisi, Giorgia
Scarpi, Emanuela
Passardi, Alessandro
Nanni, Oriana
Ragazzini, Angela
Valgiusti, Martina
Casadei Gardini, Andrea
Neri, Luca Maria
Frassineti, Giovanni Luca
Amadori, Dino
Ulivi, Paola
author_sort Marisi, Giorgia
collection PubMed
description Novel predictive biomarkers are needed to improve patient selection and optimize the use of bevacizumab (B) in metastatic colorectal cancer. We analyzed the potential of five circulating biomarkers to predict B efficacy and monitor response. Peripheral blood samples collected at baseline, at the first clinical evaluation and at progression were available for 129 patients enrolled in the prospective multicentric ITACa trial and randomized to receive FOLFOX4/FOLFIRI (CT) with (64 patients) or without B (65 patients). VEGF-A, eNOS, EPHB4, COX2 and HIF-1α mRNA levels were measured by qRT-PCR. Baseline marker expression levels and their modulation during therapy were analyzed in relation to objective response, progression-free survival and overall survival (OS). VEGF and eNOS expression was significantly correlated in both groups (Spearman’s correlation coefficient = 0.80; P < 0.0001 and 0.75; P < 0.0001, respectively). B-treated patients with >30% reduction in eNOS and VEGF levels from baseline to the first clinical evaluation showed better OS than the others (median OS 31.6 months, 95% CI 21.3–49.5 months and median OS 14.4 months, 95% CI 9.0–22.7 months, respectively, HR 0.38, 95% CI 0.19–0.78, P = 0.008). A reduction in eNOS and VEGF expression from baseline to the first clinical evaluation may indicate a response to B.
format Online
Article
Text
id pubmed-5431064
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-54310642017-05-16 Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab Marisi, Giorgia Scarpi, Emanuela Passardi, Alessandro Nanni, Oriana Ragazzini, Angela Valgiusti, Martina Casadei Gardini, Andrea Neri, Luca Maria Frassineti, Giovanni Luca Amadori, Dino Ulivi, Paola Sci Rep Article Novel predictive biomarkers are needed to improve patient selection and optimize the use of bevacizumab (B) in metastatic colorectal cancer. We analyzed the potential of five circulating biomarkers to predict B efficacy and monitor response. Peripheral blood samples collected at baseline, at the first clinical evaluation and at progression were available for 129 patients enrolled in the prospective multicentric ITACa trial and randomized to receive FOLFOX4/FOLFIRI (CT) with (64 patients) or without B (65 patients). VEGF-A, eNOS, EPHB4, COX2 and HIF-1α mRNA levels were measured by qRT-PCR. Baseline marker expression levels and their modulation during therapy were analyzed in relation to objective response, progression-free survival and overall survival (OS). VEGF and eNOS expression was significantly correlated in both groups (Spearman’s correlation coefficient = 0.80; P < 0.0001 and 0.75; P < 0.0001, respectively). B-treated patients with >30% reduction in eNOS and VEGF levels from baseline to the first clinical evaluation showed better OS than the others (median OS 31.6 months, 95% CI 21.3–49.5 months and median OS 14.4 months, 95% CI 9.0–22.7 months, respectively, HR 0.38, 95% CI 0.19–0.78, P = 0.008). A reduction in eNOS and VEGF expression from baseline to the first clinical evaluation may indicate a response to B. Nature Publishing Group UK 2017-05-02 /pmc/articles/PMC5431064/ /pubmed/28465540 http://dx.doi.org/10.1038/s41598-017-01420-0 Text en © The Author(s) 2017 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Marisi, Giorgia
Scarpi, Emanuela
Passardi, Alessandro
Nanni, Oriana
Ragazzini, Angela
Valgiusti, Martina
Casadei Gardini, Andrea
Neri, Luca Maria
Frassineti, Giovanni Luca
Amadori, Dino
Ulivi, Paola
Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
title Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
title_full Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
title_fullStr Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
title_full_unstemmed Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
title_short Circulating VEGF and eNOS variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
title_sort circulating vegf and enos variations as predictors of outcome in metastatic colorectal cancer patients receiving bevacizumab
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5431064/
https://www.ncbi.nlm.nih.gov/pubmed/28465540
http://dx.doi.org/10.1038/s41598-017-01420-0
work_keys_str_mv AT marisigiorgia circulatingvegfandenosvariationsaspredictorsofoutcomeinmetastaticcolorectalcancerpatientsreceivingbevacizumab
AT scarpiemanuela circulatingvegfandenosvariationsaspredictorsofoutcomeinmetastaticcolorectalcancerpatientsreceivingbevacizumab
AT passardialessandro circulatingvegfandenosvariationsaspredictorsofoutcomeinmetastaticcolorectalcancerpatientsreceivingbevacizumab
AT nannioriana circulatingvegfandenosvariationsaspredictorsofoutcomeinmetastaticcolorectalcancerpatientsreceivingbevacizumab
AT ragazziniangela circulatingvegfandenosvariationsaspredictorsofoutcomeinmetastaticcolorectalcancerpatientsreceivingbevacizumab
AT valgiustimartina circulatingvegfandenosvariationsaspredictorsofoutcomeinmetastaticcolorectalcancerpatientsreceivingbevacizumab
AT casadeigardiniandrea circulatingvegfandenosvariationsaspredictorsofoutcomeinmetastaticcolorectalcancerpatientsreceivingbevacizumab
AT nerilucamaria circulatingvegfandenosvariationsaspredictorsofoutcomeinmetastaticcolorectalcancerpatientsreceivingbevacizumab
AT frassinetigiovanniluca circulatingvegfandenosvariationsaspredictorsofoutcomeinmetastaticcolorectalcancerpatientsreceivingbevacizumab
AT amadoridino circulatingvegfandenosvariationsaspredictorsofoutcomeinmetastaticcolorectalcancerpatientsreceivingbevacizumab
AT ulivipaola circulatingvegfandenosvariationsaspredictorsofoutcomeinmetastaticcolorectalcancerpatientsreceivingbevacizumab